Invion

Invion Short-term Debt

The Short-Term Debt of Invion (IVX.AX) as of Oct 28, 2026 is 1.55 M AUD.

Short-term Debt

1.55 MAUD

Last updated:

Short-Term Debt of Invion is 2026 1.55 M AUD. Short-Term Debt of Invion was 2025 0.00 AUD. It decreases by % higher compared to the previous year.

The Invion Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2016
120,199.00 AUD
Jan 1, 2017
1.26 M AUD
Jan 1, 2018
20,295.00 AUD
Jan 1, 2019
50,270.00 AUD
Jan 1, 2020
11,000.00 AUD
Jan 1, 2021
11,000.00 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2026
1.55 M AUD
The Invion Short-term Debt history
YEARShort-term DebtYoY
1.55 MAUD—
0.00AUD-100.00%
11,000.00AUD0.00%
11,000.00AUD-78.12%
50,270.00AUD+147.70%
20,295.00AUD-98.39%
1.26 MAUD+945.85%
120,199.00AUD-95.34%
2.58 MAUD+16,094.07%
15,924.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Short-Term Debt of Invion is 1.55 M AUD in 2026.

On Eulerpool you can find the complete historical development of Short-Term Debt Invion since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Invion

All Key Metrics — Invion